Introduction and objectives
For patients with recurring prostate cancer around 90% of relapses occur at the location of the primary tumor. That motivates further local dose escalation to avoid enhanced doses to rectum and bladder. Boosting the dominant intraprostatic lesions (DIL) is currently explored in clinical studies. The purpose of this study was to assess the feasibility of DIL boosting with tomotherapy and to compare it dosimetrically to previously evaluated VMAT and IMPT strategies based on the same objectives [1] .
Methods
For twelve patients the DILs were defined on MRI scans and propagated to the respective CT images. For each patient a tomotherapy plan (6MV; fixed field width 1 cm; pitch 0.287, modulation factor ranged from 2.5 to 2.9) aiming at the escalation of the physical dose up to 95 Gy to the PTV DIL , with a dose prescription of 77 Gy to the PTV prostate , delivered in 35 fractions as simultaneously integrated boost, was calculated. The following hard dose constraints were applied for rectum and bladder: V 72Gy ≤ 5%, V 77Gy ≤ 1cc and V 72Gy ≤ 10% and V 80Gy ≤ 1cc, respectively. PTV DIL and PTV prostate margins were 4/5/4 mm in LR/AP/CC directions, respectively. Resulting tomotherapy plans were compared to VMAT and IMPT plans. Furthermore, pelvic floor muscles, femoral heads, urethra and penile bulb dose indices and equivalent uniform doses (EUDs) were evaluated.
Results
The median EQD 2(α/β) dose to the DIL was 113.4 Gy (IsoE) for tomotherapy while it was 2.7 Gy (IsoE) less for VMAT and 0.8 Gy (IsoE) more for IMPT. V 95% (of prescribed dose) of 83.4% and 98.1% for PTV DIL and PTV prostate were best for tomotherapy, while with VMAT and IMPT 64.5, 94.6% and 80.0 and 92.9% was achieved (cf. Figure 1) . Mean dose to the rectal wall and bladder wall were 26.4±5.0 and 19.3±5.5 Gy (IsoE) for tomotherapy, 30.5±5.0 and 21.0±5.5 Gy (IsoE) for VMAT , and 16.7±3.6 and 15.6 ±4.3 Gy (IsoE) for IMPT. The EUD for the other delineated organs was significantly lower for tomotherapy in comparison to VMAT (4.3 Gy on average), but higher than for IMPT (2.1 Gy on average). Figure 2 shows an example set of a patient's dose distributions for all three treatment techniques.
Conclusions
Tomotherapy is a suitable EBRT modality to deliver DIL boost treatments. It performs better than VMAT in terms of achievable boost doses, target coverage and OARs sparing. However, besides achievable coverage it does not surpass IMPT. Although the obtained OAR doses were higher
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